Bli medlem
Bli medlem

Du är här


DBV Technologies: DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety an

| Press Release |
| |
|Montrouge, France, February 25, 2016 |

DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin®PeanutDBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
the publication of results from a Phase Ib trial showing that Viaskin® Peanut
was observed to have a favorable safety and tolerability profile. High
adherence to treatment, which was documented by an overall 96% compliance
rate and a 4% dropout, was also observed.

This scientific publication, authored by Dr. Stacie Jones, Professor of
Pediatrics at the University of Arkansas for Medical Sciences, Chief of
Allergy and Immunology and Dr. and Mrs. Leeman King Chair in Pediatric
Allergy at Arkansas Children's Hospital in Little Rock, and entitled "Safety
of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy: A
Phase 1 Study Using Viaskin Patch
" is available online in the Journal of Allergy and Clinical Immunology

"With more than 25 years of experience in treating patients with this disease,
I believe that Viaskin Peanut, if approved, will fulfill patients and
caretakers' unmet need for a safe, effective and patient-friendly treatment,"
saidDr. Hugh Sampson
, Chief Scientific Officer of DBV Technologies. "This publication offers a
favorable view of the safety of Viaskin Peanut.
Not only were participants of all ages and varying degrees of severity
generally able to tolerate treatment, but the vast majority of study
participants adhered to the protocol, which we believe highlights the
convenience, ease of use and potential for rapid adoption of Viaskin Peanut."
The study,Safety of Epicutaneous Immunotherapy for the Treatment of Peanut
, was completed in February 2012. Following this Phase Ib trial, DBV
Technologies initiated VIPES, a dose-finding, Phase IIb clinical trial of
Viaskin Peanut in peanut allergic patients, which met its primary endpoint in
October 2014. DBV is currently studying Viaskin Peanut in PEPITES, a
randomized, double-blind, placebo-controlled pivotal registration Phase III
trial in patients 4 to 11 years of age.

One hundred individuals between the ages of six and 50 were enrolled in this
randomized, double-blind, placebo-controlled Phase Ib trial at five clinical
sites in the United States. Peanut-allergic subjects were randomized 4:1 and
treated for two weeks with Viaskin Peanut 20 µg, 100 µg 250 µg and 500 µg
doses or placebo applied to intact skin at either 24 or 48 hour intervals.
DSMB review occurred prior to progression of dosing at all stages.
"This publication reinforces the unique safety and tolerability profile of
Viaskin Peanut among a variety of patient types, increasing our enthusiasm
for its potential use as a new treatment option for the individuals who
suffer from peanut allergy,"
saidDr. Stacie Jones
In the United States, approximately three million people are reported to have
an allergy to peanuts. This allergy, which tends to develop in childhood,
typically is lifelong, and the incidence is on the rise as studies show the
number of children living with peanut allergy appears to have tripled between
1997 and 2008. (

Detailed Results of the Phase Ib Clinical Study

No reports of serious adverse events (SAEs) or epinephrine use due to
treatment occurred. Treatment emergent adverse events (TEAEs) were mostly
mild and transient with no differences among treatment groups. No severe
TEAEs were reported, and 47.5% of Viaskin Peanut treated subjects and 55% of
placebo subjects reported no TEAE. The most commonly seen TEAEs were related
to application site and included pruritus (itching), erythema (reddening),
edema (swelling) and urticarial (hives). In this study, application of
Viaskin Peanut for 24 hours demonstrated a more favorable safety and
tolerability drug profile than the 48 hour application.

The overall dropout rate was 4% (4/100). Of the four dropouts, three subjects
were in the Viaskin Peanut arm and one subject was in the placebo group.
More specifically:

* One adolescent treated with 500 µg Viaskin Peanut/48 hour was a consent
* Two active-treatment patients treated with the 48-hour application (one
child, 250 µg Viaskin Peanut/48-hours; one adult, 100 µg Viaskin
* One adult patient, who only received placebo and experienced an
anaphylactic reaction, was discontinued from the study for noncompliance
upon investigator's decision.

In this JACI publication, Dr. Jones and colleagues concluded that Epicutaneous
Immunotherapy (EPIT®) administered via Viaskin was observed to have a
favorable safety and tolerability profile, with high adherence by study

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing
in prevalence. DBV Technologies, incorporated in France in 2002, has
developed a proprietary, patented technology for administering an allergen to
intact skin while avoiding transfer to the blood, and thus lowering the risk
of a systemic, allergic reaction in the event of accidental exposure. DBV
Technologies is focusing on food allergies, including milk and peanut, for
which there are currently no effective treatments. DBV Technologies has
designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The
clinical development program for Viaskin® Peanut has received Fast Track
designation and Breakthrough Therapy designation from the U.S. Food and Drug

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of
American Depositary Shares (each representing one-half of one ordinary share)
(Ticker: DBVT). For more information on DBV Technologies, please visit our

Forward Looking Statements

This press release contains forward-looking statements forward-looking
statements that are not promises or guarantees and involve substantial risks
and uncertainties. The Company's product candidates have not been approved
for sale in any jurisdiction. Among the factors that could cause actual
results to differ materially from those described or projected herein are
uncertainties associated generally with research and development, clinical
trials and related regulatory reviews and approvals, the risk that historical
preclinical results may not be predictive of future clinical trial results,
and the risk that historical clinical trial results may not be predictive of
future trial results. A further list and description of these risks,
uncertainties and other risks can be found in the Company's regulatory
filings with the French Autorité des Marchés Financiers, the Company's
Securities and Exchange Commission filings and reports, including in the
Company's Annual Report on Form 20-F for the year ended December 31, 2014 and
future filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. DBV Technologies
undertakes no obligation to update or revise the information contained in
this Press Release, whether as a result of new information, future events or
circumstances or otherwise.

| DBV Technologies Contacts |
| Nathalie Donne Susanna Mesa |
| |
| VP Finance, US Investor Relations&Strategy |
|Director, Corporate Communication&Business Development Tel. : +1 212-271-0861 |
| |
|Tel. : +33(0)1 55 42 78 72 |
| |
| |
| DBV Technologies Media Contacts US&Europe |
| Marion Janic Caroline Carmagnol |
| |
| |
|Rooney&Associates Alize RP - Relation Presse |
| |
|Tel. : +1-212-223-4017 Tel. : +33(0)6 64 18 99 59 |
| |
Erinn White

Centron PR
Tel. : +1-646-722-8822

PDF Version


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.